v3.25.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Sep. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 3,862.8 $ 2,375.0
Marketable securities 97.6 0.0
Inventory 2,209.4 2,460.5
Other current assets 916.8 752.5
Total current assets 8,936.6 7,456.8
Property, plant and equipment, net 3,075.7 3,181.3
Operating lease assets 330.5 356.4
Intangible assets, net 9,331.9 9,691.2
Goodwill 6,490.7 6,478.9
Deferred tax asset 312.4 324.2
Investments and other assets 729.7 560.5
Total assets 29,207.5 28,049.3
Current liabilities:    
Current portion of notes payable 0.0 1,748.6
Taxes payable 103.3 548.3
Accounts payable 413.1 424.2
Accrued expense and other 2,773.6 2,807.7
Total current liabilities 3,290.0 5,528.8
Notes payable 6,285.1 4,547.2
Deferred tax liability 358.1 190.5
Long-term operating lease liabilities 305.0 334.5
Other long-term liabilities 761.8 732.3
Total liabilities 11,000.0 11,333.3
Commitments, contingencies and guarantees
Biogen Inc. shareholders’ equity:    
Preferred stock, par value $0.001 per share 0.0 0.0
Common stock, par value $0.0005 per share 0.1 0.1
Additional paid-in capital 797.7 569.4
Accumulated other comprehensive income (loss) (214.8) (136.2)
Retained earnings 20,601.6 19,259.8
Treasury stock, at cost (2,977.1) (2,977.1)
Total equity 18,207.5 16,716.0
Total liabilities and equity 29,207.5 28,049.3
Nonrelated Party    
Current assets:    
Accounts receivable, net of allowance for doubtful accounts of $3.1 and $2.2, respectively 1,374.1 1,404.8
Related Party    
Current assets:    
Accounts receivable, net of allowance for doubtful accounts of $3.1 and $2.2, respectively $ 475.9 $ 464.0